Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E29.00 EPS (ttm)13.85 Insider Own0.10% Shs Outstand234.61M Perf Week-4.23%
Market Cap94.25B Forward P/E20.14 EPS next Y19.95 Insider Trans-22.45% Shs Float234.43M Perf Month-6.93%
Income3.28B PEG1.64 EPS next Q3.91 Inst Own92.60% Short Float1.11% Perf Quarter12.36%
Sales10.13B P/S9.30 EPS this Y58.40% Inst Trans0.29% Short Ratio1.37 Perf Half Y29.97%
Book/sh46.00 P/B8.73 EPS next Y17.53% ROA24.70% Target Price480.37 Perf Year36.25%
Cash/sh7.87 P/C51.07 EPS next 5Y17.64% ROE32.80% 52W Range275.39 - 480.18 Perf YTD18.34%
Dividend- P/FCF- EPS past 5Y29.90% ROI26.20% 52W High-17.49% Beta1.03
Dividend %- Quick Ratio1.70 Sales past 5Y17.30% Gross Margin88.10% 52W Low43.86% ATR12.79
Employees7550 Current Ratio2.10 Sales Q/Q20.00% Oper. Margin43.20% RSI (14)35.57 Volatility2.23% 2.31%
OptionableYes Debt/Eq0.05 EPS Q/Q72.80% Profit Margin32.40% Rel Volume1.61 Prev Close401.71
ShortableYes LT Debt/Eq0.05 EarningsApr 24 BMO Payout0.00% Avg Volume1.90M Price396.18
Recom2.00 SMA20-6.18% SMA50-5.64% SMA20011.50% Volume909,142 Change-1.38%
Mar-23-15Downgrade Stifel Buy → Hold
Feb-02-15Reiterated Argus Buy $385 → $440
Jan-30-15Reiterated RBC Capital Mkts Outperform $400 → $445
Jan-30-15Reiterated Deutsche Bank Buy $430 → $460
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Mar-19-14Reiterated Stifel Buy $360 → $376
Mar-07-14Reiterated Barclays Overweight $325 → $352
Mar-03-14Reiterated Stifel Buy $330 → $360
Jan-30-14Reiterated UBS Neutral $300 → $310
Jan-30-14Reiterated Brean Capital Buy $293 → $377
Jan-30-14Reiterated Argus Buy $310 → $360
Jan-28-14Reiterated Deutsche Bank Buy $340 → $415
Jan-27-14Reiterated Canaccord Genuity Buy $291 → $355
Jan-16-14Reiterated Stifel Buy $296 → $321
Jan-10-14Reiterated Barclays Overweight $285 → $325
Dec-20-13Reiterated RBC Capital Mkts Outperform $275 → $325
Apr-27-15 10:10AM  Company News for April 27, 2015 - Corporate Summary
09:30AM  The Zacks Analyst Blog Highlights: Biogen, NV5 Holdings, Tractor Supply, ULTA Salon, Cosmetics & Fragrance and Intuit - Press Releases
08:57AM  ABWUPDATE 2-Rare diseases drugmaker Sobi jumps on takeover bid Reuters
08:30AM  Short Sellers Become More Wary of Big Biotech at 24/7 Wall St.
03:07AM  Sweden's Sobi confirms in preliminary talks on bid for company
Apr-26-15 08:25PM  Pharmaceutical company Sobi said to be open to sale -Bloomberg
08:14PM  10-Q for Biogen Idec, Inc. at Company Spotlight
08:01PM  [$$] Safety Worries Damp Sales of Biogens MS Drug Tecfidera at The Wall Street Journal
Apr-25-15 04:05PM  Swedish Orphan Said to Be Open to Sale Amid Boom in Drug Deals at Bloomberg
04:05PM  Swedish Orphan Said to Be Open to Sale Amid Boom in Drug Deals
01:02PM  Trusty Horses; Tools, Pizza and Shoes: Jim Cramer's Best Blogs TheStreet
Apr-24-15 11:55PM  Biogens Tough Treatment from Wall Street at The Wall Street Journal -6.64%
06:29PM  With Market Back In Uptrend, IBD 50 Growth Names Thrive at Investor's Business Daily
06:19PM  Humana (HUM), Gilead Sciences (GILD), McKesson Corporation (MCK) Among Sivik Globals Top Healthcare Stocks at Insider Monkey
05:18PM  Stock Pops & Drops: DDD, DNKN, BIIB & WFM
05:11PM  Biogen's MS Drug Sales Light, Alzheimer's Data Pushed Back
04:00PM  Techs surge on earnings, boosts Nasdaq, S&P 500 to record close at CNBC
03:29PM  Biogen's Tough Treatment from Wall Street at The Wall Street Journal
03:14PM  Biogen Shares Not Too Healthy After Q1 Miss
03:00PM  Biogen blames lower-than-expected Tecfidera sales partly on safety concerns at bizjournals.com
03:00PM  Chips Fall, But Nasdaq Holds Up; Avago Slices 50-Day Line at Investor's Business Daily
02:58PM  Biogen: Buy the Selloff at Barrons.com
02:35PM  Biogen Q1 Misses Estimates As Tecfidera Stalls at Investor's Business Daily
12:24PM  Trader blitz: AAL, DDD & more
12:06PM  Here are five stocks making huge moves today
11:51AM  Biogen says Tecfidera sales slow, delays data readout on Alzheimer's drug Reuters
11:47AM  Jim Cramer Loves Regeneron, Sees Shares Headed to $500 at TheStreet
11:39AM  US STOCKS-Nasdaq hits 15-year high, propelled by Amazon, Microsoft
11:01AM  Biogen: Significant Drop Follows 'Significant Slowing' at Barrons.com
10:52AM  Biogen Misses on 1Q Earnings, Tecfidera Falls Short - Analyst Blog
09:56AM  Morgan Stanley Reviews Biogen Earnings
09:55AM  Cramer's Stop Trading: Regeneron gets to $500
09:46AM  Biogen shares are tanking because a 71% surge in profits just wasn't enough
09:45AM  Will Biogen Earnings Interrupt the Biotech Bull Market? at 24/7 Wall St.
09:42AM  Biogen (BIIB) Stock Falls Today on Weak First Quarter Earnings Results at TheStreet
09:05AM  Wall Street eyes data, Greece meeting at CNBC
08:34AM  Biogen (BIIB) Misses on 1Q Earnings & Revenues - Tale of the Tape
08:25AM  Biogen Profit Falls Short at The Wall Street Journal
08:09AM  Early movers: BIIB, XRX, MSFT, AMZN, SBUX & more at CNBC
08:04AM  Morning Movers: Biogen Drops on Big Miss; Starbucks Soars at Barrons.com
08:00AM  Biogen Inc Earnings Call scheduled for 8:00 am ET today
07:38AM  Biogen quarter-one results disappoint Wall Street as Tecfidera sales slow
07:25AM  Biogen Reports First Quarter 2015 Revenues of $2.6 Billion at noodls
07:22AM  Biogen misses Street 1Q forecasts
07:14AM  Biogen Profit Falls Short of Estimates as Tecfidera Growth Slows at Bloomberg
07:12AM  BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:07AM  Biogen 1st qtr profit jumps 71 pct as MS drug Tecfidera shines Reuters
07:07AM  Q1 2015 Biogen Idec Inc Earnings Release - Before Market Open
07:00AM  Biogen Reports First Quarter 2015 Revenues of $2.6 Billion Business Wire
06:10AM  Wall Street looks to finish week strong at CNBC
12:01AM  American Airlines, Biogen, Xerox earnings in focus at MarketWatch
Apr-23-15 07:45PM  Biogen Earnings Preview: What To Look For at Investor's Business Daily
06:42PM  Technology in focus, with one eye on Greece at CNBC
06:21PM  Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog
06:16PM  Acorda Reports Encouraging Data on MS Drug - Analyst Blog
06:12PM  Emergent BioSolutions Resumes BioThrax Manufacturing - Analyst Blog
04:57PM  Will Biogen's (BIIB) Earnings Streak Continue in 1Q? - Analyst Blog
04:36PM  Ultragenyx Announces Positive Data from Triheptanoin Study - Analyst Blog
02:53PM  Four trades to go before the closing bell at CNBC
02:33PM  What to Watch in the Day Ahead - Friday, April 24 Reuters
02:05PM  Should Biogen and Shire investors be wary of the latest patent challenges? at bizjournals.com
12:58PM  Top trades for the 2nd half: Dunkin, HSBC & more
11:18AM  AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog
06:40AM  What do Biogen, LinkedIn, and Lannett have in common?
Apr-22-15 04:45PM  15 'Sustainable' Companies Not Named Apple to Buy Right Now at TheStreet
04:21PM  Billionaire Stanley Druckenmiller Squashed the Market in Q1 With These Top Picks at Insider Monkey
02:45PM  Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog
02:30PM  Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog
01:21PM  Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
01:15PM  Hedge fund manager targets patent for Biogen's blockbuster MS drug, Tecfidera at bizjournals.com
01:00PM  Will Edwards Lifesciences (EW) Top Q1 Earnings Estimates? - Analyst Blog
12:58PM  Kyle Bass Challenges Biogen Fumaderm Patent
11:43AM  Technological Innovation Increases Amgens Earnings and Stock Price
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals - Press Releases
09:00AM  Perrigo Beats on Q3 Earnings, Gives View, Rejects Mylan Bid - Analyst Blog
05:02AM  Roche more confident in beating Alzheimer's after Biogen data
Apr-21-15 05:10PM  Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog
03:14PM  Is AbbVie (ABBV) Set to Top 1Q Earnings on Humira & HCV? - Analyst Blog
02:00PM  Will Baxter's (BAX) Earnings Disappoint Estimates in Q1? - Analyst Blog
09:25AM  Fate Therapeutics (FATE) Jumps: Stock Moves 12.4% Higher - Tale of the Tape
07:30AM  PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients Business Wire
07:30AM  International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction Business Wire
Apr-20-15 05:58PM  Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog
02:58PM  Will Amgen (AMGN) Keep Earnings Streak Alive in 1Q? - Analyst Blog
01:44PM  CAR-T Therapy Stocks Hit Hard Following AACR Data
01:29PM  Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog
11:18AM  5 Biotech Earnings Under The Microscope This Week
08:36AM  Clovis Oncology (CLVS) Falls: Stock Goes Down 5.3% - Tale of the Tape
07:30AM  TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients Business Wire
Apr-19-15 02:50PM  Why This Trader Likes Gilead Better Than Biogen
Apr-18-15 08:02AM  Meet 4 IBD 50 Companies Reporting Earnings This Week at Investor's Business Daily
12:01AM  Two Styles, One Vision at Barrons.com
Apr-17-15 04:53PM  Biotech Investors Shouldn't Miss These Stocks This Earnings - Earnings ESP
04:31PM  It's A Big Weekend For Biotech
01:44PM  Biotech investors brace for updates on key drugs at CNBC
01:17PM  FDA approves generic version of top-selling MS drug Copaxone
01:05PM  Why These May Be the Top 4 Growth Stocks of 2015 at Investopedia
04:00AM  French firm's drug succeeds in pivotal trial for progressive MS
Apr-16-15 06:16PM  VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog
06:14PM  AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company's products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer's disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,134Apr 03 04:24 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale423.201,362576,39843,814Apr 02 04:29 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 27Sale430.12430184,9528,574Mar 30 04:13 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Option Exercise65.855,066333,57137,577Mar 26 04:31 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Sale449.0612,0105,393,21125,567Mar 26 04:31 PM
Rowinsky Eric KDirectorMar 20Option Exercise59.8211,667697,92022,977Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 20Sale475.0011,6675,541,82511,310Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 19Option Exercise59.822,333139,56013,643Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 19Sale436.142,3331,017,50811,310Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 17Option Exercise59.824,667279,18015,977Mar 18 05:03 PM
Rowinsky Eric KDirectorMar 17Sale425.454,6671,985,58911,310Mar 18 05:03 PM
DiPietro KennethEVP Human ResourcesMar 16Sale415.46803333,6140Mar 17 08:10 PM
SCANGOS GEORGE AChief Executive OfficerMar 13Sale412.69537221,61345,176Mar 16 08:39 PM
PANGIA ROBERT WDirectorMar 10Option Exercise47.713,625172,95417,998Mar 11 04:13 PM
SHERWIN STEPHEN ADirectorMar 10Option Exercise59.826,000358,92010,150Mar 11 04:17 PM
SHERWIN STEPHEN ADirectorMar 10Sale409.676,0002,458,0204,150Mar 11 04:17 PM
PANGIA ROBERT WDirectorMar 10Sale413.403,6251,498,57814,873Mar 11 04:13 PM
Rowinsky Eric KDirectorMar 09Option Exercise59.824,666279,12015,976Mar 11 04:15 PM
Rowinsky Eric KDirectorMar 09Sale417.234,6661,946,79511,310Mar 11 04:15 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 02Sale409.493,1741,299,7159,004Mar 03 04:44 PM
SCANGOS GEORGE AChief Executive OfficerMar 02Sale410.67825338,80345,713Mar 03 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 19Sale401.04537215,35846,538Feb 20 04:28 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale389.11825321,01647,075Feb 18 04:45 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 17Sale389.112,128828,0264,321Feb 18 04:41 PM
DiPietro KennethEVP Human ResourcesFeb 17Sale389.111,188462,263803Feb 18 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 17Sale389.11418162,64815,004Feb 18 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.0015,599045,547Feb 17 09:32 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.0047101,450Feb 17 09:16 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.003,63407,152Feb 17 08:54 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,20101,318Feb 17 08:50 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.001,605015,805Feb 17 08:47 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.004,299022,960Feb 17 08:44 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,738033,214Feb 17 08:40 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.005,200016,481Feb 17 08:37 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.003,769028,634Feb 17 08:34 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,76402,706Feb 17 08:30 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.003,60108,771Feb 17 08:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833043,148Feb 11 04:25 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 10Sale398.111,143455,03914,574Feb 11 04:26 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691022,194Feb 10 05:06 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691032,744Feb 10 05:07 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82407,088Feb 10 05:08 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,398Feb 10 05:11 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270029,255Feb 11 04:25 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909027,716Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Sale398.05856340,73114,574Feb 10 05:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498024,625Feb 10 05:12 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468014,542Feb 10 05:14 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277015,851Feb 10 05:11 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70505,802Feb 10 05:10 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,63606,147Feb 10 05:08 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023029,590Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191018,646Feb 10 05:06 PM
DiPietro KennethEVP Human ResourcesFeb 02Sale389.031,656644,2340Feb 03 06:35 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 02 07:46 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,157013,133Feb 02 07:43 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,15705,157Feb 02 07:40 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM